Double-blind, placebo-controlled 5-period crossover HV study (n=31) testing four intravenous DMT infusion schedules (total doses 0, 54, 69, 90, 115 mg) to characterise subjective and autonomic effects.
This randomised, quadruple-blind, five-period crossover study in healthy volunteers compares four intravenous DMT administration schemes and placebo using a bolus and maintenance perfusion model to produce a stable, prolonged DMT experience.
Primary aims are to test dose–response relationships and to compare bolus-plus-perfusion versus perfusion-only schedules on pharmacokinetic, subjective and autonomic outcomes; safety and tolerability are systematically recorded.
Bolus of 0 mg DMT + perfusion of 0 mg/min DMT over 60 min (saline).
Saline bolus and 0 mg/min perfusion (placebo).
Intravenous perfusion 0.6 mg/min over 90 min (no bolus).
Bolus 0 mg + perfusion 0.6 mg/min over 90 min (total 54 mg).
Bolus 15 mg + perfusion 0.6 mg/min over 90 min.
Bolus 15 mg + perfusion 0.6 mg/min over 90 min (total 69 mg).
Intravenous perfusion 1 mg/min over 90 min (no bolus).
Bolus 0 mg + perfusion 1 mg/min over 90 min (total 90 mg).
Bolus 25 mg + perfusion 1 mg/min over 90 min.
Bolus 25 mg + perfusion 1 mg/min over 90 min (total 115 mg).